Things are moving forward nicely and fast now and all ingredients are now assembled to make a great event out of the NP2D congress in Zermatt by the end of this year are now assembled. As you will find out below, we already have almost 100 confirmed participants, and expect another 100 or so registrations.
We have the confirmed participation of delegations from major companies such as Amgen (USA), Aventis Pharma (Germany), Bachem (sponsor, Switzerland and USA), Debiopharm (Switzerland), DSM Research (Netherlands), Genzyme Corporation (USA), Genzyme Pharmaceuticals (exhibitor, Switzerland and USA), Lonza (Switzerland), Novo Nordisk (Denmark), Novozymes (exhibitor, Denmark), Palatin Technologies (USA), Pentapharm (Switzerland), Peptisynta (Belgium), PolyPhor (Switzerland), Senn Chemicals (Switzerland), Serono (sponsor, Switzerland), Trimeris (USA), UCB-Bioproducts (Belgium) and John Wiley (partner, UK).
Companies such as Atheris Laboratories (Switzerland), Biométhodes (France), CellPep (France), ConoGenetix (Germany), Dictagene (Switzerland), Direvo Biotech (Germany), Galenika (Yugoslavia), GeneBio (Switzerland), Genepep (France), Jerini (Germany), MondoBiotech (Switzerland), Pevion Biotech (Switzerland), Planton (Germany), Procyon Biopharma (Canada), Selecore (germany), TheraNostics (Germany), Theraptosis (France), Theratechnologies (Canada) and Xenome (Australia) will also attend, as well as earlier stage start-ups like Airmid (USA), Alecor (Australia), Chaperone Technologies (USA), Cyclagen (Australia), Kalthera (Australia) or FunZyme Biotechnologies (Switzerland).
Major Universities from all continents (Adelaide, Arizona, Belo Horizonte, Ben Gurion, Britisch Columbia, Brisbane, Calgary, California, Copenhagen, Davis, Frederiksberg, Geneva, Indiana, Irvine, Minas Gerais, Oslo, Patras, Queensland, Showa, Stellenbosch, Temple, Tromsø, Utrecht, Singapore, etc.) and institutions such as the Pasteur Institute (France), the Center for Applied Toxinology (Brazil), The Butantan Institute (Brazil), the Commissariat à l’Energie Atomique (France) and the Wistar Institute (USA) will be present with outstanding scientific contributions.
Additionally, venture capital companies such as SPEF Venture (Natexis Private Equity, France), as well as Nlight! Marketing & Communication in Life Sciences (Switzerland), OLPE Pharmaceutical Consultants (USA), and local biotech incubators.
We are convinced that this will be an excellent opportunity for your organisation and give you access to great networking opportunities.
The event will bring together a broad range of scientists from the academia and from the industry who share the same interest for peptide based drugs, even though they come from different horizons and from all around the world. Amongst all participants you will for example have a chance to meet with the following key opinion leaders:
Dr Thierry Abribat, Teratechnologies, Canada
Prof. Paul Alewood, University of Queensland, Australia
Dr Diane Alewood, Xenome Ltd, Brisbane, Australia
Dr Mimoun Ayoub, Genzyme Pharmaceuticals, Basel, Switzerland
Dr Pierre Barthelemy, Peptisyntha S.A., Belgium
Dr Silke Behne, AplaGen GmbH, Germany
Prof. Daniel Bertrand, University of Geneva, Switzerland
Dr Kamel Besseghir, Debiopharm S.A., Switzerland
Dr Vincent Bille, UCB-Bioproducts, Belgium
Dr Arya Biragyn, GRC, National Institute on Aging, National Institutes of Health, USA
Dr Corina Borghouts-Heinz, Georg Speyer Haus, Germany
Dr Daniel Bourgin, Lonza, Basel, Switzerland
Prof. Eefjan Breukink, Utrecht University, Netherlands
Dr Philippe Bulet, Atheris Laboratories, Geneva, Switzerland
Prof. Antonio Camargo, Butantan Institute, Sao Paolo, Brazil
Dr Fabio Cavalli, MondoBiotech Group, Switzerland
Prof. George Chandy, University of California Irvine & Airmid Ltd, USA
Dr José de Chastonay, Bachem Americas, California, USA
Prof. David Craik, University of Queensland, Cyclagen and Kalthera Pty Ltd, Australia
Prof. Paul Cordopatis, University of Patras, Greece
Dr Bonabes de Rougé, CellPep S.A., Paris, France
Prof. Richard DiMarchi, Indiana University, USA
Dr Vincent Dive, CEA-Saclay, Paris, France
Prof. Tomas Ganz, University of California Los Angeles, USA
Prof. Ponnampalan Gopalakrishnakone, University of Singapore, Singapore
Dr Stuart Hamilton, Senn Chemicals A.G., Switzerland
Prof. Bob Hancock, University of British Columbia, Vancouver, Canada
Ass. Prof. Paul Robert Hansen, Department of Natural Sciences, RVAU, Denmark
Prof. Shigesada Higuchi, Showa University School of Pharmaceutical Sciences, Japan
Dr Peter Hoffmann, Genzyme Pharmaceuticals, Cambridge, USA
Dr Ron Hogg, University of Geneva, Switzerland
Mr Dan Ifrah, research assistant, Natural Sciences, RAVU, Denmark
Dr Etienne Jacotot, Theraptosis S.A. & Pasteur Institute, Paris, France
Dr Laurent Jeannin, Peptisyntha S.A., Belgium
Dr Eva Jung, Aventis Pharma, Franfurt am Mein, Germany
Prof. Marguerite Kay, Institute for Biomedical Sciences and Technology, Temple, USA
Dr Oliver Kensch, Direvo Biotech A.G., Germany
Dr Peter Klein, Pevion Biotech A.G., Switzerland
Dr Michael Kleine, Planton GmbH, Kiel, Germany
Dr Andreas Klosterman, ConoGenetix Biosciences, Germany
Dr Kodra János, Novo Nordisk A/S, Denmark
Dr Harald Kolmar, Selecore GmbH, Germany
Prof. Sofiya Kolusheva, Ben-Gurion University, Israël
Dr Jesper Lau, Novo Nordisk A/S, Denmark
Dr Beatriz Lieblich-Fernandez, Butantan Institute, Sao Paolo, Brazil
Dr Peter Madsen, Novo Nordisk A/S, Denmark
Dr Ingrid Marshal, Biométhodes, Evry, France
Prof. John Marchalonis, University of Arizona/ College of Medicine, USA
Prof. André Ménez, CEA-Saclay, Paris, France
Dr Michel Mollard, SPEF Venture, Paris, France
Dr Les Miranda, Amgen Inc, California, USA
Dr Geneviève Motte, UCB-Bioproducts, Belgium
Dr Per Holse Mygind, Novozyme A/S, Denmark
Prof. Jon Nissen-Meyer, University of Oslo, Norway
Dr Daniel Obrecht, Polyphor AG, Basel, Switzerland
Dr Jean-Pierre Obrecht, Polyphor A.G., Basel, Switzerland
Prof. Robin Offord, University of Geneva, Switzerland
Dr Laszlo Otvos, Wistar Institute & OLPE Pharmaceutical Consultants, Philadelphia, USA
Dr Chandra Panchal, Procyion Biopharma, Montreal, Canada
Dr Michael Pennington, Bachem Bioscience, Pennsylvania, USA
Mrs Anna-Maria Perchuc, Pentapharm A.G., Basel, Switzerland
Dr Adriano Pimenta, Federal University of Minas Gerais, Brazil
Dr Karine Puget, Genepep, Montpellier, France
Dr Doniyor Pulatov, Tashkent Medical Institute, Uzbekistan
Dr Peter Quaedflieg, DSM Research, Netherlands
Dr Milena Radeta, Galenika, Yugoslavia
Prof. Marina Rautenbach, University of Stellenbosch, South Africa
Dr Ulrich Reineke, Jerini Pharmaceuticals, Berlin, Germany
Mrs Trine S. Ryge, PhD student, Department of Natural Sciences, RVAU, Denmark
Dr Mario Roggero, UCB-Bioproducts, Belgium
Prof. Keith Rose, University of Geneva, Switzerland
Dr Jean-Marc Sabatier, University of Marseille and CellPep S.A., France
Dr Martin Schneider, Senn Chemicals A.G., Switzerland
Dr Stephen Schneider, Trimeris, Durham, NC, USA
Dr Shubh Sharma, Palatin Technologies, USA
Dr Jörg Stockhaus, ConoGetetix Biosciences, Germany
Dr Andy Strong, Dictagene, Lausanne, Switzerland
Prof. John S. Svendsen, University of Tromsø, Denmark
Prof. Mike Tyler, University of Adelaide, Australia
Dr Charlotte Hummer Vad, Novozyme A/S, Denmark
Dr Lambert Van Orsouw, Direvo Biotech A.G., Germany
Prof. Hans Vogel, University of Calgary, Canada
Dr Wim Jan Vrijbloed, Polyphor A.G., Basel, Switzerland
Dr Christina Wedemeyer, Genzyme Pharmaceuticals, Switzerland
Dr Timothy Wells, Serono International, Geneva, Switzerland
Dr Oleg Werbitzky, Lonza, Visp, Switzerland
Dr Heike Wulff, University of California, Davis, USA
Dr Rinaldo Zurbriggen, Pevion Biotech Ltd, Switzerland
